<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Arrhythmias in COPD
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Arrhythmias in COPD
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Arrhythmias in COPD
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Omar A Minai, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Madias, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Umur Hatipoglu, MD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of chronic obstructive pulmonary disease (COPD) includes gradually worsening shortness of breath and functional limitation, caused by a progressive decline in lung function and the development of co-morbid illnesses [
         <a href="#rid1">
          1
         </a>
         ]. Multifocal atrial tachycardia, atrial fibrillation, and ventricular arrhythmias are common co-morbidities among patients with COPD [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The potential contributing factors, occurrence rates, and management of arrhythmias in patients with COPD will be discussed here. The management of stable COPD and atrial and ventricular arrhythmia is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/943.html" rel="external">
          "Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          POTENTIAL CONTRIBUTING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple factors have been evaluated as possible contributors to the development of arrhythmias in patients with COPD [
         <a href="#rid3">
          3,4
         </a>
         ]. Some are related to comorbid disease processes with shared risk factors and others are more specifically related to COPD. Factors related to COPD that have been studied regarding their potential role in arrhythmia development are discussed in greater detail below.
        </p>
        <p class="headingAnchor" id="H2391188">
         <span class="h2">
          Comorbid disease processes
         </span>
         <span class="headingEndMark">
          —
         </span>
         COPD shares risk factors (eg, age, smoking) with a number of disease processes and related treatments that are also associated with cardiac arrhythmias, including [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronary heart disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertensive heart disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right and/or left ventricular failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypokalemia and hypomagnesemia
        </p>
        <p>
        </p>
        <p>
         These comorbid disease processes are discussed separately in the topics about the individual arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Prevalence'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/966.html" rel="external">
          "Left ventricular hypertrophy and arrhythmia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2391311">
         <span class="h2">
          Hypoxemia and respiratory acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxemia and respiratory acidosis have been identified in case series as factors associated with the development of arrhythmias among patients with COPD [
         <a href="#rid3">
          3,4
         </a>
         ]. The exact mechanisms by which hypoxemia and acidosis provoke arrhythmias are unclear. One possible explanation comes from the observation that norepinephrine levels (compared with normal values) were elevated in hypercapnic, hypoxemic patients with COPD who were hospitalized with fluid retention and peripheral edema [
         <a href="#rid5">
          5
         </a>
         ]. It is hypothesized that the low arterial blood pressure caused by hypercapnia contributed to the elevation in norepinephrine. The catecholamine activation may in turn contribute to development of arrhythmias in such patients.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Theophylline
         </span>
         <span class="headingEndMark">
          —
         </span>
         Though less commonly used in contemporary COPD management,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         has numerous well-characterized cardiac effects, including a dose-dependent increase in heart rate, enhancement of atrial automaticity, and acceleration of intracardiac conduction. Theophylline is also associated with rhythm disturbances, such as sinus tachycardia, premature atrial complex (PAC; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat), supraventricular tachycardia, atrial fibrillation, unifocal and multifocal atrial tachycardia, and ventricular arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'
         </a>
         .)
        </p>
        <p>
         The frequency of atrial and ventricular arrhythmias increases with the serum
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         level, as illustrated in these studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a cross-sectional, retrospective study of 100 patients, the heart rate was directly related to the serum
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         concentration, and the serum theophylline concentration was the strongest independent predictor of arrhythmia [
         <a href="#rid6">
          6
         </a>
         ]. Patients with a serum concentration of theophylline (10 to 20 mcg/mL [56 to 111 micromol/L]) had an odds ratio for arrhythmia of 3.7, when compared with those patients who had serum theophylline levels of less than 2.5 mcg/mL. Multifocal atrial tachycardia (MAT) was found in 8 percent of patients with a serum theophylline concentration of 10 to 20 mcg/mL compared with 16 percent of those with values greater than 20 mcg/mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study prospectively evaluated arrhythmias among 16 patients with
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         toxicity (a serum theophylline concentration exceeding 30 mcg/mL) [
         <a href="#rid7">
          7
         </a>
         ]. Sinus tachycardia and ventricular premature beats (VPBs) were the most common arrhythmias, occurring in 85 percent and 80 percent of subjects, respectively. The frequency and complexity of ventricular ectopy were largely influenced by the theophylline concentration and by coexistent conditions, such as underlying ischemic heart disease and age. Potentially life-threatening arrhythmias were rare (one patient had ventricular tachycardia), and only one patient required intervention with antiarrhythmic therapy.
        </p>
        <p>
        </p>
        <p>
         However, the magnitude of the effect of low therapeutic doses of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         on the occurrence of arrhythmias is unclear, and the current target trough serum level is lower (5 to 12 mcg/mL [28 to 67 micromol/L]) than the range used in earlier studies (10 to 20 mcg/mL [56 to 111 micromol/L]) [
         <a href="#rid6">
          6,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Beta-adrenergic agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled beta-2 adrenergic agonists are a mainstay of therapy for COPD, but have the potential to increase heart rate and may increase cardiac arrhythmias via nonselective beta-adrenergic effects [
         <a href="#rid9">
          9
         </a>
         ]. However, a number of studies support the overall safety of inhaled selective beta-2 adrenergic agonists.
        </p>
        <p>
         The effect of nebulized
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         on sinus and atrioventricular (AV) node activity was examined in a study of 18 patients with asthma or mild COPD [
         <a href="#rid10">
          10
         </a>
         ]. Nebulized albuterol (5 mg) shortened the sinus cycle length and sinus node recovery time. In addition, administration of albuterol enhanced the AV nodal conduction, reduced AV nodal refractory time, and decreased myocardial refractory time.
        </p>
        <p>
         Despite the effect of
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         on sinus and AV nodal conduction noted above, clinical studies suggest that inhaled selective beta-adrenergic agonists infrequently cause serious arrhythmias. A meta-analysis of 33 randomized trials of patients receiving beta-agonists for obstructive airways disease revealed that beta-adrenergic agonists were associated with an increased risk of sinus tachycardia (RR 3.06, 95% CI 1.7-5.5), but were not associated with a significantly increased risk of major adverse cardiovascular events (composite endpoint of ventricular tachycardia, atrial fibrillation, syncope, heart failure, myocardial infarction, cardiac arrest, and sudden death) [
         <a href="#rid11">
          11
         </a>
         ]. A single inhaled dose of beta-agonist increased the heart rate (mean 9 beats per minute, 95% CI 5.32-12.92). The effect of high-dose albuterol for COPD exacerbations was not addressed in this study.
        </p>
        <p>
         The effect of long-acting beta-agonists (LABA) on heart rate and development of arrhythmia has also been examined. An analysis of the data from two trials examining the effect of LABAs on heart rate and cardiac arrhythmias found a slight increase in atrial tachycardias, but no increase in mean heart rate or risk of serious arrhythmias [
         <a href="#rid12">
          12,13
         </a>
         ]. A third trial of 1429 patients with COPD found that administration of a LABA (
         <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">
          arformoterol
         </a>
         or
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         ) did not result in a statistically significant increase of atrial arrhythmias [
         <a href="#rid12">
          12
         </a>
         ]. The role of LABAs in the management of COPD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management", section on 'Long-acting beta-agonists'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12245074">
         <span class="h2">
          Cigarette smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether cigarette smoke exposure increases the risk of arrhythmias, independent of the degree of airflow obstruction, is unclear. It is hypothesized that active cigarette smoking may increase the risk of arrhythmias, due to profibrotic effects of nicotine on myocardial tissue or an increased susceptibility to catecholamines, but this has not been definitively demonstrated [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/932.html" rel="external">
          "Supraventricular premature beats", section on 'Etiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Cardiac autonomic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alterations of cardiac autonomic function may be important in the development of arrhythmia in patients with COPD. Some patients with COPD lack the normal pattern of cardiac circadian rhythm changes and some have a prolonged QT interval [
         <a href="#rid15">
          15,16
         </a>
         ]. An absence of the normal nocturnal decrease in sympathetic tone among patients with COPD is suggested by 24-hour ambulatory electrocardiographic (ECG) recordings that do not reveal the typical nocturnal slowing of the heart rate. It has been suggested that this altered circadian pattern may predispose to arrhythmia [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Ventricular diastolic dysfunction and respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of arrhythmias in COPD has been associated with concurrent left ventricular diastolic dysfunction. In a series of 22 patients with COPD, diastolic dysfunction was the only clinical variable predictive of ventricular premature beats [
         <a href="#rid17">
          17
         </a>
         ]. Among patients with COPD, ventricular diastolic dysfunction may be related to right ventricular overload from pulmonary hypertension or to common causes such as increased age or comorbid myocardial ischemia or systemic hypertension. (See
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p>
         Respiratory failure may also contribute to the risk of arrhythmias. In the preceding study of diastolic dysfunction in COPD, PAC correlated with hypoxemia and hypercarbia [
         <a href="#rid17">
          17
         </a>
         ]. Furthermore, the number of arrhythmias significantly decreased when the respiratory failure improved.
        </p>
        <p class="headingAnchor" id="H874419">
         <span class="h2">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exercise does not appear to increase the risk of serious arrhythmias in patients with severe COPD [
         <a href="#rid18">
          18,19
         </a>
         ]. In a case series of 122 patients with severe COPD, for example, ventricular arrhythmias (eg, VPBs ≥6/min, bigeminy, multiform VPBs, couplets, or nonsustained ventricular tachycardia [VT]) developed during exercise in 12 percent [
         <a href="#rid19">
          19
         </a>
         ]. None of these required specific treatment. Half of the patients who had ventricular arrhythmias during exercise had similar or lower grade ventricular arrhythmias at rest prior to testing. Patients without a history of ischemic heart disease or without any evidence of a cardiac arrhythmia at rest have a low likelihood of developing serious arrhythmias during exercise [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H883203">
         <span class="h1">
          OCCURRENCE OF ARRHYTHMIAS IN PATIENTS WITH COPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence and prevalence of atrial and ventricular arrhythmias among patients with COPD varies widely among reported studies [
         <a href="#rid12">
          12,20-22
         </a>
         ]. This variation may be due to differences in the study populations (eg, severity of COPD, presence of respiratory failure), the presence or absence of ventricular failure or underlying cardiac disease, the methodology used to record the arrhythmias (a single electrocardiogram [ECG] versus a continuous 24-hour recording), and the medications used in management of COPD (eg,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         , beta-adrenergic agonists).
        </p>
        <p class="headingAnchor" id="H883462">
         <span class="h2">
          Holter monitoring in stable COPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac arrhythmias, both supraventricular and ventricular, are significantly more common among patients with COPD compared to those without, with a prevalence that varies according to the severity of underlying COPD [
         <a href="#rid3">
          3,12,23
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among a cohort of 7441 patients (mean age 64 years, 49 percent female) who underwent clinically indicated pulmonary function testing as well as 24-hour Holter monitoring between 2000 and 2009, 3121 patients (41.9 percent) were diagnosed with COPD [
         <a href="#rid23">
          23
         </a>
         ]. Patients diagnosed with COPD were significantly more likely to have atrial fibrillation/atrial flutter (23 versus 11 percent), nonsustained ventricular tachycardia (13 versus 6 percent), or sustained ventricular tachycardia (1.6 versus 0.9 percent), than those without COPD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a cohort of 69 hypoxemic patients with severe but stable COPD who underwent continuous ECG recordings, episodes of supraventricular tachycardia occurred in 69 percent, while atrial fibrillation was the underlying rhythm in 7 percent [
         <a href="#rid3">
          3
         </a>
         ]. Premature ventricular beats (primarily multiform) and nonsustained ventricular tachycardia were present in 83 percent and 22 percent, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H883478">
         <span class="h2">
          Specific arrhythmias associated with COPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multifocal atrial tachycardia (MAT), atrial fibrillation, and ventricular arrhythmias often complicate the course of COPD, particularly during acute exacerbations [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H883521">
         <span class="h3">
          Multifocal atrial tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         MAT is defined by the following electrocardiographic findings  (
         <a class="graphic graphic_waveform graphicRef127222" href="/z/d/graphic/127222.html" rel="external">
          waveform 1
         </a>
         ) [
         <a href="#rid24">
          24,25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discrete P waves with at least
         <strong>
          three
         </strong>
         different morphologies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial rate faster than 100 beats per minute
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Separation of the P waves by isoelectric intervals
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variable P-P intervals, P-R duration, and R-R intervals
        </p>
        <p>
        </p>
        <p>
         The evaluation and diagnosis of MAT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Clinical manifestations and diagnosis'
         </a>
         .)
        </p>
        <p>
         In patients with COPD, MAT most commonly develops in the setting of an acute exacerbation, but is also associated with certain drugs (eg,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ), other pulmonary processes (eg, pneumonia, pulmonary embolism, hypoxemia), and nonpulmonary disorders such as hypokalemia, hypomagnesemia, and chronic renal failure [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Associated clinical conditions'
         </a>
         .)
        </p>
        <p>
         Among patients with chronic airway obstruction who were admitted to the hospital with acute respiratory failure, MAT was noted in 17 percent [
         <a href="#rid26">
          26
         </a>
         ]. However, this report may be an overestimate of the frequency of MAT as concomitant medications were not reported, and the study was performed in an era when
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         and nonselective beta-agonists were widely used. In a systematic review that examined the contribution of COPD to the development of MAT, COPD was present in 55 percent of patients with MAT, making it the most common pulmonary disorder associated with MAT [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The rapid ventricular response in MAT likely contributes to the respiratory impairment in patients with COPD, either by elevation of the left ventricular diastolic pressure or by limiting the portion of the cardiac cycle spent in diastole [
         <a href="#rid27">
          27
         </a>
         ]. This increase in left ventricular pressure can contribute to pulmonary hypertension, potentially increasing right atrial pressure in addition to increasing left atrial pressure and augmenting the stimulus for MAT.
        </p>
        <p class="headingAnchor" id="H883569">
         <span class="h3">
          Atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation is characterized by an irregularly irregular rhythm and the absence of distinct P waves on the ECG and can be a cause of worsening dyspnea and hypoxemia among patients with COPD. The diagnosis of atrial fibrillation and the evaluation of predisposing conditions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery"
         </a>
         .)
        </p>
        <p>
         The prevalence of atrial fibrillation appears to be increasing among patients admitted with a COPD exacerbation. Analysis of data from the Nationwide Inpatient Sample (a publicly available all-payer United States database) between 2003 and 2014 identified 1,345,270 oxygen-dependent patients admitted with COPD exacerbation [
         <a href="#rid28">
          28
         </a>
         ]. The prevalence of atrial fibrillation exceeded 21 percent of study patients in 2014, compared with 12.9 percent in 2003. Patients with concurrent atrial fibrillation were at significantly higher risk of death, respiratory failure, and need for assisted ventilation among other comorbidities.
        </p>
        <p>
         The likelihood of developing new atrial fibrillation in patients with COPD is higher than patients without lung disease. Among subjects in the Copenhagen City Heart Study who met spirometric criteria for COPD, the incidence of new onset atrial fibrillation was 0.9 percent over five years of follow up compared with 0.4 percent among those with normal spirometry [
         <a href="#rid20">
          20
         </a>
         ]. In several series of ambulatory patients with COPD, the risk of developing atrial fibrillation increased as the forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) decreased [
         <a href="#rid20">
          20,29,30
         </a>
         ]. In addition, atrial fibrillation is associated with higher symptom burden, worse quality of life, and worse cardiovascular outcomes among patients with COPD than those without [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Atrial fibrillation is also increased during and after acute exacerbations of COPD. Among 152 patients hospitalized with an exacerbation of COPD, 24 hour Holter monitoring revealed permanent or paroxysmal atrial fibrillation in 30 and 12 percent, respectively [
         <a href="#rid22">
          22
         </a>
         ]. In a separate series of 944 patients with atrial fibrillation following an acute exacerbation of COPD, the rate of atrial fibrillation was significantly higher within the first 90 days following COPD exacerbation compared with the reference period of 90 days preceding COPD exacerbation (14.1 versus 7.3 per 100 person-months, rate ratio 1.9; 95% CI 1.6-2.3) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H883562">
         <span class="h3">
          Ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventricular arrhythmias, ranging from isolated ventricular premature beats (VPBs) to nonsustained ventricular tachycardia, are often noted on 24 hour ECG monitoring of patients with COPD [
         <a href="#rid21">
          21-23,33
         </a>
         ]. The evaluation and diagnosis of ventricular tachycardia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/933.html" rel="external">
          "Nonsustained VT in the absence of apparent structural heart disease"
         </a>
         .)
        </p>
        <p>
         The frequency of ventricular arrhythmias among patients with COPD has been examined in several studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 6351 consecutive patients with COPD who underwent Holter monitoring and pulmonary function testing, ventricular tachycardia (VT) was almost twice as likely to occur among those with COPD than without (23 versus 13 percent); COPD and VT remained independently associated after adjusting for left ventricular ejection fraction, demographics, and other comorbidities [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a case control study, PVCs were more common among outpatients with COPD than controls (924 +/- 493 beats versus 35 +/- 23 beats); nonsustained ventricular tachycardia was noted in 8 patients (27 percent) with COPD, but none of the controls [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1291532">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         When managing arrhythmias in patients with COPD, treatment measures are tailored to the specific type and severity of the arrhythmia and the unique clinical characteristics of each patient. Certain general measures are useful in the majority of patients, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimization of COPD management – Optimal management of COPD includes providing supplemental oxygen (aiming for a pulse oxygen saturation of 90 to 94 percent), reversing bronchoconstriction, and treating hypercapnia with bronchodilation and respiratory support. Selective, short-acting beta-adrenergic agents are a key therapy for exacerbations of COPD and should be titrated to provide adequate bronchodilation and relief of dyspnea without excess cardiac chronotropic effects. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Oxygen therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Home/office short-acting bronchodilator treatments'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction of precipitating conditions – Acute myocardial ischemia, and electrolyte, acid-base, and metabolic abnormalities, particularly hypokalemia and hypomagnesemia, should be identified and treated. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Magnesium and potassium repletion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Triggers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of the concurrent use of drugs that can prolong the QT interval – Drugs that can prolong the QT interval include
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , and certain psychotropic medications  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ). QT prolongation can initiate ventricular tachycardias, particularly torsade de pointes [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cautious dosing or discontinuation of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         – For patients on chronic theophylline therapy, maintain the serum level at 8 to 12 mcg/mL (44 to 67 micromol/L), since 85 percent of its beneficial effect occurs at a level of 12 mcg/mL or less, and theophylline may be arrhythmogenic even at levels previously considered within the therapeutic range (10 to 20 mcg/mL or 56 to 111 micromol/L) [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Theophylline'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12244686">
         <span class="h2">
          Multifocal atrial tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific antiarrhythmic therapy is indicated for multifocal atrial tachycardia (MAT) when the rapid ventricular response produces or worsens ischemia, heart failure, or peripheral perfusion. The general management of multifocal atrial tachycardia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         When pharmacologic intervention is indicated for MAT, the preferred agents are
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (
         <a class="graphic graphic_table graphicRef83358" href="/z/d/graphic/83358.html" rel="external">
          table 2
         </a>
         ). Due to the potential risk of bronchoconstriction from beta-blocking agents, verapamil is most commonly used as the initial agent in patients with COPD. Metoprolol is reserved for use when verapamil does not provide adequate rate control. The dosing and administration of verapamil and metoprolol are presented in the table  (
         <a class="graphic graphic_table graphicRef83358" href="/z/d/graphic/83358.html" rel="external">
          table 2
         </a>
         ) and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
         When administering
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         to patients with COPD, we continuously monitor pulse oximetry and provide supplemental oxygen, aiming for a pulse oxygen saturation of 90 to 94 percent. Theoretically, calcium channel blockers may lower the partial pressure of arterial oxygen in patients with lung disease due to the relief of hypoxic vasoconstriction in pulmonary arteries/arterioles supplying poorly ventilated areas. This possibility was supported by pooled data from several studies that found a mean reduction in arterial oxygen tension from 105 to 78 mmHg after the administration of a calcium channel blocker, a change that may be clinically significant [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Oxygen therapy'
         </a>
         .)
        </p>
        <p>
         Despite concerns about beta-blockers triggering bronchoconstriction in patients with COPD, a systematic review found that the beta-1 selective agent
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         resulted in a decrease in ventricular response of 24 to 40 percent among the four studies described (45 patients) without exacerbating respiratory symptoms [
         <a href="#rid25">
          25
         </a>
         ]. A separate systematic review did not find evidence of adverse respiratory effects with short-term use of cardioselective beta-blockers in patients with COPD who did not have active wheezing or bronchoconstriction [
         <a href="#rid37">
          37
         </a>
         ]. For patients with COPD that is not characterized by a bronchospastic component, cautious use of metoprolol is a reasonable option, when
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         is ineffective. (See
         <a class="medical medical_review" href="/z/d/html/967.html" rel="external">
          "Major side effects of beta blockers", section on 'Increased airways resistance'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         is generally used in preference to
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         for MAT due to the limited supportive data for diltiazem, although success was reported with an initial bolus and maintenance infusion in a case series [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1291289">
         <span class="h2">
          Atrial fibrillation and supraventricular tachyarrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American College of Cardiology/American Heart Association and European Society of Cardiology have published recommendations for the management of atrial fibrillation in patients with pulmonary disease  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid38">
          38-40
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urgent electrical cardioversion of supraventricular tachyarrhythmias is indicated if hemodynamic collapse, angina, or heart failure is present. For patients who have not been anticoagulated or have suboptimal anticoagulation, a transesophageal echocardiogram is frequently performed to exclude intracardiac thrombus just prior to cardioversion. (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pharmacologic therapy to terminate the arrhythmia or control the ventricular response is indicated if these maneuvers are unsuccessful  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ). The management of atrial fibrillation and other supraventricular tachyarrhythmias is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         (not available as an intravenous preparation in the United States) is an alternative therapy for restoring normal sinus rhythm in patients with COPD and atrial fibrillation [
         <a href="#rid39">
          39
         </a>
         ]. Flecainide should be avoided in patients with underlying left heart failure or myocardial ischemia. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Specific antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antithrombotic therapy is initiated in patients with atrial fibrillation based on standard practices, although anticoagulation has not been studied specifically in patients with atrial fibrillation in the setting of chronic lung disease. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of patients presenting with atrial fibrillation will require slowing of the ventricular rate to improve symptoms. Nondihydropyridine calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ) have generally been the preferred pharmacologic therapy for new onset atrial fibrillation in patients with COPD, as these agents have a weak bronchodilator effect, rather than the potential bronchoconstrictive effect of noncardioselective beta blockers  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid38">
          38,39
         </a>
         ]. However, beta blockers are generally more effective at achieving adequate ventricular rate control and retrospective data from a nationwide database suggest that beta blockers might actually be safer than calcium channel blockers [
         <a href="#rid41">
          41,42
         </a>
         ]. While the retrospective database study did not find an increase in mortality with nonselective beta blockers among patients with COPD [
         <a href="#rid42">
          42
         </a>
         ], the use of cardioselective beta blockers is preferred. Doses of nondihydropyridine calcium channel blockers and the beta blocker
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         are provided in the table  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         offers no advantages over calcium channel blockers for patients with atrial fibrillation and COPD, except in the presence of heart failure, and some data suggest a higher mortality in patients treated with digoxin monotherapy  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid38">
          38,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several effective antiarrhythmic drugs must be used with caution or not at all in patients with COPD [
         <a href="#rid38">
          38,39
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Beta blockers are contraindicated in patients with uncontrolled bronchospasm and wheezing. Similar considerations apply to
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         , a Class IC antiarrhythmic  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 4
         </a>
         ), and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , a class III agent, which have beta-blocking properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Because of the overlap of many risk factors between COPD and coronary heart disease and the frequent co-existence of these two processes, Class IA and IC antiarrhythmic drugs  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 4
         </a>
         ) should be used with caution as these drugs are contraindicated in patients with coronary heart disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          Adenosine
         </a>
         , which has a rapid onset of action and an effect that is blocked by
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         , may provoke bronchospasm and must be used with caution in patients with COPD [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy may cause pulmonary toxicity. Although initial reports suggested a 5 to 15 percent incidence, the incidence appears to be lower (1 to 5 percent) with lower maintenance doses used in contemporary practice, although pulmonary toxicity has been reported with low cumulative doses. In patients with preexisting lung disease such as COPD, chronic therapy should be used with caution or avoided given the potential risk of superimposed lung toxicity in those with limited respiratory reserve [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">
          "Amiodarone pulmonary toxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Society guidelines suggest avoiding beta-adrenergic agonists in patients with atrial fibrillation based on low quality evidence [
         <a href="#rid38">
          38
         </a>
         ]. We make the decision regarding use of beta-adrenergic agonists on a case-by-case basis. For patients with difficulty achieving rate control but without active bronchoconstriction, it is reasonable to avoid or minimize the dose of beta agonists. On the other hand, for patients with dyspnea and uncontrolled bronchoconstriction, treatment with beta-2 selective adrenergic agonists is appropriate and generally well-tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We generally avoid initiation of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         in patients with atrial fibrillation, particularly if rate control has been problematic [
         <a href="#rid38">
          38
         </a>
         ]. For patients with new onset atrial fibrillation in the setting of chronic theophylline therapy, we ensure that the dose of theophylline is in the low therapeutic range (8 to 12 mcg/mL [44 to 67 micromol/L]) or discontinue it if it is not felt to be vital to the treatment of the patient’s COPD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Symptomatic ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic ventricular arrhythmias require prompt treatment. Electrical cardioversion should immediately be performed if hemodynamic collapse, myocardial ischemia, or ventricular failure is present. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/968.html" rel="external">
          "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         Pharmacologic treatment is indicated for the symptomatic patient who is not hemodynamically compromised. The pharmacologic therapy of ventricular arrhythmias is discussed separately, but some caveats regarding treatment in patients with COPD are discussed below. (See
         <a class="medical medical_review" href="/z/d/html/968.html" rel="external">
          "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management"
         </a>
         .)
        </p>
        <p>
         When managing patients with COPD and ventricular arrhythmias, it is important to consider potential adverse effects of antiarrhythmic medications on lung function.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is the most commonly used agent for ventricular arrhythmias. While patients with COPD are not necessarily at higher risk of amiodarone pulmonary toxicity, they may be at higher risk for respiratory failure if toxicity occurs [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">
          "Amiodarone pulmonary toxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         has a significant nonselective beta-blocking effect, which can trigger bronchospasm, and thus is usually avoided in patients with COPD and active bronchoconstriction. (See
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol", section on 'Major side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          Mexiletine
         </a>
         is another alternative but is of variable efficacy and interacts with
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         via CYP1A2 inhibition.
        </p>
        <p>
        </p>
        <p>
         An implantable cardioverter-defibrillator (ICD) may be indicated for long-term management of patients with clinically significant (symptomatic and/or sustained) ventricular arrhythmias. In a case-control study of patients with COPD and a left ventricular ejection fraction of 35 percent or less, patients with an ICD had a lower total mortality (odds ratio 0.18, 95% CI 0.06–0.56) [
         <a href="#rid44">
          44
         </a>
         ]. A discussion of the indications for ICD placement is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28202146">
         <span class="h2">
          Asymptomatic ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal management of asymptomatic ventricular arrhythmias in patients with COPD is not known. Approximately 4 percent of patients with COPD experience sudden or unexplained death; however, the role of serious ventricular arrhythmias in these deaths is poorly defined [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         The benefit of treating asymptomatic ventricular arrhythmias in an attempt to lessen the risk of sudden death in these patients also remains unproven. Antiarrhythmic drugs may actually increase risk of arrhythmias, worsen heart failure, and cause lung injury [
         <a href="#rid24">
          24,46
         </a>
         ]. Thus, considerable caution should be exercised in administering antiarrhythmic drugs to asymptomatic patients with COPD and ventricular arrhythmias. Given the potential risks, we avoid pharmacologic antiarrhythmic therapy in these patients. (See
         <a class="medical medical_review" href="/z/d/html/917.html" rel="external">
          "Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H231974">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of arrhythmias on the prognosis of patients with COPD is dependent on the clinical setting (eg, severity of COPD exacerbation), presence of comorbidities (eg, shock, heart failure, stroke, renal insufficiency), and the specific arrhythmia [
         <a href="#rid47">
          47-49
         </a>
         ]. Among 69 ambulatory patients monitored as part of the nocturnal oxygen therapy trial, the presence of asymptomatic ventricular arrhythmias was not a predictor of death [
         <a href="#rid3">
          3
         </a>
         ]. In contrast, among patients hospitalized with an exacerbation of COPD, the development of multifocal atrial tachycardia (MAT) was associated with increased mortality with one series reporting an in-hospital mortality of 46 percent [
         <a href="#rid24">
          24
         </a>
         ]. MAT and other serious atrial arrhythmias can be associated with malignant ventricular arrhythmias in patients with acute respiratory failure [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         In an observational cohort study of 1013 patients with severe exacerbations of COPD, arrhythmias were a risk factor for mortality (odds ratio 2.70, 95% CI 1.40–5.22) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3959820996">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">
          "Society guideline links: Chronic obstructive pulmonary disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H777653">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Both supraventricular and ventricular arrhythmias are common among patients with chronic obstructive pulmonary disease (COPD). The risk is further elevated during periods of acute exacerbation and thoracic surgery. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Occurrence of arrhythmias in patients with COPD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Multiple factors contribute to the development of arrhythmias in patients with COPD, including hypoxemia, respiratory acidosis, electrolyte disturbances, medications, systemic hypertension, cardiac autonomic dysfunction, coronary heart disease, and heart failure. (See
         <a class="local">
          'Potential contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common arrhythmias in patients with COPD
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multifocal atrial tachycardia
         </strong>
         <strong>
          (MAT)
         </strong>
         – Characteristic features of MAT include discrete P waves with at least
         <strong>
          three
         </strong>
         different morphologies, an atrial rate faster than 100 beats/min, isoelectric intervals separating the P waves, and variability in the P-P intervals, P-R duration, and R-R intervals. MAT most commonly develops in the setting of an acute exacerbation of COPD. (See
         <a class="local">
          'Multifocal atrial tachycardia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atrial fibrillation
         </strong>
         – Atrial fibrillation is characterized by an irregularly irregular rhythm and the absence of distinct P waves. New onset of atrial fibrillation is associated with advancing COPD but may also lead to increasing dyspnea and hypoxemia. (See
         <a class="local">
          'Atrial fibrillation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventricular arrhythmias
         </strong>
         – Ventricular tachyarrhythmias, ranging from isolated premature ventricular contractions (PVCs) to nonsustained ventricular tachycardia, are common in ambulatory and hospitalized patients with COPD. It appears unlikely that asymptomatic ventricular arrhythmias adversely impact mortality among ambulatory patients with COPD. (See
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General measures, regardless of arrhythmia type
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolic and electrolyte disturbances
         </strong>
         – The treatment of arrhythmias in patients with COPD begins with correction of hypoxemia, respiratory acidosis, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), and cardiac ischemia. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management of COPD medications
         </strong>
         – Medications that can prolong the QT interval should be avoided and arrhythmogenic drugs such as
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         should be decreased in dose or discontinued. Short-acting selective beta-2 adrenergic agents should be titrated to provide adequate bronchodilation and relief of dyspnea without excess cardiac chronotropic effects. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of MAT
         </strong>
         – For patients with MAT in the setting of an exacerbation of COPD, the main treatment is directed toward reversing bronchoconstriction and improving gas exchange. Pharmacologic therapy for MAT is indicated when a rapid ventricular response produces or worsens cardiac or peripheral ischemia heart failure or hypoxemia. For most patients with COPD and symptomatic MAT, we suggest using
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); metoprolol may be used as add-on therapy if necessary in those without active bronchoconstriction  (
         <a class="graphic graphic_table graphicRef83358" href="/z/d/graphic/83358.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of atrial fibrillation and atrial flutter
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          In those with shock, angina, or heart failure
         </strong>
         – Urgent electrical cardioversion of atrial fibrillation or atrial flutter is indicated if hemodynamic collapse, angina, or heart failure is present. (See
         <a class="local">
          'Atrial fibrillation and supraventricular tachyarrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pharmacologic rate control, for
         </strong>
         <strong>
          those without shock, angina, or heart failure
         </strong>
         – For stable patients with atrial fibrillation or flutter and COPD, we suggest using
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         for rate control (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Metoprolol is reserved for patients without uncontrolled bronchoconstriction who do not respond to the calcium channel blockers. For those with an accessory pathway or heart failure,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         are preferred  (
         <a class="graphic graphic_table graphicRef83353" href="/z/d/graphic/83353.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Atrial fibrillation and supraventricular tachyarrhythmias'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antithrombotic therapy
         </strong>
         – For patients with atrial fibrillation, antithrombotic therapy is initiated based on standard practices. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiarrhythmic therapy
         </strong>
         – Several drugs that are effective antiarrhythmics (eg,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         ) must be used with caution or avoided in patients with COPD. (See
         <a class="local">
          'Atrial fibrillation and supraventricular tachyarrhythmias'
         </a>
         above and
         <a class="local">
          'Symptomatic ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of ventricular arrhythmias
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic ventricular arrhythmias
         </strong>
         – Urgent treatment with either cardioversion (in unstable patients) or antiarrhythmics (in those without instability) is required for symptomatic ventricular arrhythmias. (See
         <a class="local">
          'Symptomatic ventricular arrhythmias'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/968.html" rel="external">
          "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic ventricular arrhythmias
         </strong>
         – For patients with COPD and asymptomatic ventricular arrhythmias, we avoid antiarrhythmic therapy due to uncertain benefit and the potential for a proarrhythmic effect. (See
         <a class="local">
          'General measures'
         </a>
         above and
         <a class="local">
          'Asymptomatic ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H970872691">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Minai OA, Benditt J, Martinez FJ. Natural history of emphysema. Proc Am Thorac Soc 2008; 5:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011; 32:2365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Górecka D. Cardiac arrhythmias in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1997; 52:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992; 86:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991; 99:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16:360.
          </a>
         </li>
         <li class="breakAll">
          Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallergis EM, Manios EG, Kanoupakis EM, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005; 127:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008; 87:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008; 2:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Alessandro A, Boeckelmann I, Hammwhöner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol 2012; 19:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tükek T, Yildiz P, Atilgan D, et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int J Cardiol 2003; 88:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995; 89:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Incalzi RA, Pistelli R, Fuso L, et al. Cardiac arrhythmias and left ventricular function in respiratory failure from chronic obstructive pulmonary disease. Chest 1990; 97:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheong TH, Magder S, Shapiro S, et al. Cardiac arrhythmias during exercise in severe chronic obstructive pulmonary disease. Chest 1990; 97:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konecny T, Somers KR, Park JY, et al. Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. Heart Rhythm 2018; 15:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rusinowicz T, Zielonka TM, Zycinska K. Cardiac Arrhythmias in Patients with Exacerbation of COPD. Adv Exp Med Biol 2017; 1022:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konecny T, Park JY, Somers KR, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014; 114:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne, RM. Management of arrhythmias in patients with severe lung disease. Clin Pulm Med 1994; 1:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCord J, Borzak S. Multifocal atrial tachycardia. Chest 1998; 113:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 1973; 63:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engel TR, Radhagopalan S. Treatment of multifocal atrial tachycardia by treatment of pulmonary insufficiency: or is it vice versa? Chest 2000; 117:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao X, Han H, Wu C, et al. Prevalence of Atrial Fibrillation in Hospital Encounters With End-Stage COPD on Home Oxygen: National Trends in the United States. Chest 2019; 155:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtzman D, Aronow WS, Mellana WM, et al. Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic. Ann Noninvasive Electrocardiol 2011; 16:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibata Y, Watanabe T, Osaka D, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 2011; 8:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durheim MT, Holmes DN, Blanco RG, et al. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018; 104:1850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirayama A, Goto T, Shimada YJ, et al. Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Subsequent Risk of Emergency Department Visits and Hospitalizations for Atrial Fibrillation. Circ Arrhythm Electrophysiol 2018; 11:e006322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz P, Tükek T, Akkaya V, et al. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. Chest 2002; 122:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg, YJ, Rosenfeld, LE. Evaluating and managing arrhythmias in COPD. J Respir Dis 1995; 16:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers RM, Owens GR, Pennock BE. The pendulum swings again. Toward a rational use of theophylline. Chest 1985; 87:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37:2893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao TF, Liu CJ, Tuan TC, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 2015; 132:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           You SC, An MH, Yoon D, et al. Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease. Heart Rhythm 2018; 15:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy JI Jr. Clinical aspects of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razak E, Kamireddy S, Saba S. Implantable cardioverter-defibrillators confer survival benefit in patients with chronic obstructive pulmonary disease. Pacing Clin Electrophysiol 2010; 33:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med 2012; 106:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt CM. Asymptomatic ventricular arrhythmias in patients with obstructive lung disease. Should they be treated? Chest 1988; 94:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM 2010; 103:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ongel EA, Karakurt Z, Salturk C, et al. How do COPD comorbidities affect ICU outcomes? Int J Chron Obstruct Pulmon Dis 2014; 9:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts CM, Stone RA, Lowe D, et al. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011; 8:354.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1454 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18453357" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Natural history of emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21875856" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2454781" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9270257" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cardiac arrhythmias in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1617764" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2036824" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2394145" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824553" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Respiratory medications and the risk of cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824553" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Respiratory medications and the risk of cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15947320" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute electrophysiologic effects of inhaled salbutamol in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15189956" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19011503" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124372" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22779085" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nicotine, cigarette smoking and cardiac arrhythmia: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714199" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7709006" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2331902" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cardiac arrhythmias and left ventricular function in respiratory failure from chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7663796" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary rehabilitation in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2323248" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cardiac arrhythmias during exercise in severe chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12797497" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28986334" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28573445" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cardiac Arrhythmias in Patients with Exacerbation of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24878126" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Management of arrhythmias in patients with severe lung disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440591" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Multifocal atrial tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4122207" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10631189" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of multifocal atrial tachycardia by treatment of pulmonary insufficiency: or is it vice versa?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30684473" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prevalence of Atrial Fibrillation in Hospital Encounters With End-Stage COPD on Home Oxygen: National Trends in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21251131" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21897765" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29875139" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30354294" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Subsequent Risk of Emergency Department Visits and Hospitalizations for Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475847" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Ventricular arrhythmias in patients with COPD are associated with QT dispersion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Evaluating and managing arrhythmias in COPD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3971750" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The pendulum swings again. Toward a rational use of theophylline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2188131" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Multifocal atrial tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16235327" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cardioselective beta-blockers for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24685669" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27567408" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26384160" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Rate-control treatment and mortality in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509364" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2182273" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical aspects of amiodarone pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20487355" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Implantable cardioverter-defibrillators confer survival benefit in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22100536" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cause-specific mortality adjudication in the UPLIFT®COPD trial: findings and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3383635" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Asymptomatic ventricular arrhythmias in patients with obstructive lung disease. Should they be treated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660633" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predicting outcomes following hospitalization for acute exacerbations of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25378919" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : How do COPD comorbidities affect ICU outcomes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579551" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21864116" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
